{"id":"https://openalex.org/W2884954262","doi":null,"title":"A Comparison of Management Strategies and Treatment Results for Neovascular Age-Related Macular Degeneration with a Focus on the Treat-Extend-Stop Protocol","display_name":"A Comparison of Management Strategies and Treatment Results for Neovascular Age-Related Macular Degeneration with a Focus on the Treat-Extend-Stop Protocol","alternate_titles":[],"publication_year":2018,"publication_date":"2018-06-19","ids":{"openalex":"https://openalex.org/W2884954262","mag":"2884954262"},"language":"en","primary_location":{"id":"mag:2884954262","doi":null,"is_oa":true,"landing_page_url":"https://www.longdom.org/open-access/a-comparison-of-management-strategies-and-treatment-results-for-neovascular-agerelated-macular-degeneration-with-a-focus-on-the-tr.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S4210233480","display_name":"Journal of Eye Diseases and Disorders","issn_l":"2684-1622","issn":["2684-1622"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320466","host_organization_name":"OMICS Publishing Group","host_organization_lineage":["https://openalex.org/P4310320466"],"host_organization_lineage_names":["OMICS Publishing Group"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Journal of Eye Diseases and Disorders","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2884954262"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.longdom.org/open-access/a-comparison-of-management-strategies-and-treatment-results-for-neovascular-agerelated-macular-degeneration-with-a-focus-on-the-tr.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030763962","display_name":"Siyang Chaili","orcid":"https://orcid.org/0000-0003-3115-6553","observed_orcids":["https://orcid.org/0000-0003-3115-6553"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Siyang Chaili","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3115-6553","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5047968636","display_name":"Sean D. Adrean","orcid":"https://orcid.org/0000-0001-6004-0643","observed_orcids":["https://orcid.org/0000-0001-6004-0643"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Adrean Sean D","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"2018","issue":"3","first_page":"1","last_page":"4"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11377","display_name":"Retinal and Macular Surgery","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neovascular-age-related-macular-degeneration","display_name":"neovascular age-related macular degeneration","score":1.0},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.9430000185966492},{"id":"https://openalex.org/keywords/treat-and-extend-regimen","display_name":"treat-and-extend regimen","score":0.7979999780654907},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.6520000100135803},{"id":"https://openalex.org/keywords/visual-acuity-outcomes","display_name":"visual acuity outcomes","score":0.8650000095367432},{"id":"https://openalex.org/keywords/treatment-strategy-comparison","display_name":"treatment strategy comparison","score":0.3889999985694885}],"concepts":[{"id":"https://openalex.org/C2780699112","wikidata":"https://www.wikidata.org/wiki/Q7246796","display_name":"Pro re nata","level":5,"score":0.8910396695137024},{"id":"https://openalex.org/C2776403814","wikidata":"https://www.wikidata.org/wiki/Q27429789","display_name":"Macular degeneration","level":2,"score":0.868382453918457},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8674132227897644},{"id":"https://openalex.org/C2781359195","wikidata":"https://www.wikidata.org/wiki/Q5105209","display_name":"Choroidal neovascularization","level":3,"score":0.643397331237793},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.5655633211135864},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.5105215311050415},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.4640025496482849},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4638414978981018},{"id":"https://openalex.org/C2781100027","wikidata":"https://www.wikidata.org/wiki/Q414270","display_name":"Ranibizumab","level":4,"score":0.46145758032798767},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.45981937646865845},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.43467992544174194},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4171636700630188},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18467387557029724},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.15213409066200256}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2884954262","doi":null,"is_oa":true,"landing_page_url":"https://www.longdom.org/open-access/a-comparison-of-management-strategies-and-treatment-results-for-neovascular-agerelated-macular-degeneration-with-a-focus-on-the-tr.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S4210233480","display_name":"Journal of Eye Diseases and Disorders","issn_l":"2684-1622","issn":["2684-1622"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320466","host_organization_name":"OMICS Publishing Group","host_organization_lineage":["https://openalex.org/P4310320466"],"host_organization_lineage_names":["OMICS Publishing Group"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Journal of Eye Diseases and Disorders","raw_type":null}],"best_oa_location":{"id":"mag:2884954262","doi":null,"is_oa":true,"landing_page_url":"https://www.longdom.org/open-access/a-comparison-of-management-strategies-and-treatment-results-for-neovascular-agerelated-macular-degeneration-with-a-focus-on-the-tr.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S4210233480","display_name":"Journal of Eye Diseases and Disorders","issn_l":"2684-1622","issn":["2684-1622"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320466","host_organization_name":"OMICS Publishing Group","host_organization_lineage":["https://openalex.org/P4310320466"],"host_organization_lineage_names":["OMICS Publishing Group"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Journal of Eye Diseases and Disorders","raw_type":null},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W160762057","https://openalex.org/W633153563","https://openalex.org/W1481978003","https://openalex.org/W1601975653","https://openalex.org/W1870696162","https://openalex.org/W1968773603","https://openalex.org/W1996171994","https://openalex.org/W2004117352","https://openalex.org/W2011187017","https://openalex.org/W2041610458","https://openalex.org/W2068742492","https://openalex.org/W2073370253","https://openalex.org/W2083043469","https://openalex.org/W2124415048","https://openalex.org/W2171962482","https://openalex.org/W2172453889","https://openalex.org/W2178063321","https://openalex.org/W2265083335","https://openalex.org/W2266679784","https://openalex.org/W2311124170","https://openalex.org/W2324412557","https://openalex.org/W2325448373","https://openalex.org/W2344762856","https://openalex.org/W2517412234","https://openalex.org/W2607892673","https://openalex.org/W2747836769","https://openalex.org/W2758021947","https://openalex.org/W2786342493","https://openalex.org/W2915852396"],"related_works":["https://openalex.org/W2914247846","https://openalex.org/W2786342493","https://openalex.org/W3182777314","https://openalex.org/W4206733210","https://openalex.org/W2758021947","https://openalex.org/W2462339036","https://openalex.org/W2519403553","https://openalex.org/W4221099874","https://openalex.org/W4403209182","https://openalex.org/W3095700978"],"abstract_inverted_index":{"Neovascular":[0],"Age-Related":[1],"Macular":[2],"Degeneration":[3],"(nAMD)":[4],"is":[5,37,102,111,152,169,188],"a":[6,41,53,99,132,149,160,192],"leading":[7,286],"cause":[8],"of":[9,43,122,135,184,194,222,228,247,252,257,292,297],"blindness,":[10],"but":[11],"the":[12,60,65,91,106,123,178,185,195,235,277],"management":[13],"has":[14],"been":[15,29],"revolutionized":[16],"by":[17,83,115],"anti-vascular":[18],"endothelial":[19],"growth":[20],"factor":[21],"(anti-VEGF)":[22],"agents.":[23],"Three":[24],"main":[25],"treatment":[26,168,217],"strategies":[27],"have":[28],"developed":[30,89],"to":[31,117,131,208,255,263,269,287],"manage":[32],"nAMD.":[33],"The":[34],"first":[35],"method":[36,68,88,237],"fixed":[38],"interval":[39,57,108,134],"dosing,":[40],"mainstay":[42],"randomized":[44],"clinical":[45],"trials":[46],"(RCT),":[47],"where":[48,71],"patients":[49,72,130,155,179],"receive":[50],"treatments":[51,141],"on":[52,59,78],"monthly":[54],"or":[55,211],"bimonthly":[56],"based":[58,77],"anti-VEGF":[61,293],"agent.":[62],"Shortly":[63],"thereafter,":[64],"pro-re-nata":[66],"(PRN)":[67],"was":[69,90,243],"introduced,":[70],"were":[73],"treated":[74,97],"as":[75],"needed":[76],"OCT":[79],"status,":[80],"usually":[81,114],"preceded":[82],"three":[84,226],"loading":[85],"doses.":[86],"Another":[87],"TreatAnd-Extend":[92],"regimen":[93],"(TAE).":[94],"Patients":[95],"are":[96,156,180],"until":[98,177],"dry":[100],"macula":[101],"obtained":[103],"and":[104,138,171,284,290],"then":[105,139,157,172],"time":[107,256],"between":[109],"injections":[110,224],"gradually":[112],"increased,":[113],"one":[116],"two-week":[118,175],"intervals.":[119],"A":[120],"variation":[121],"TAE":[124],"protocol,":[125],"termed":[126],"TreatExtend-Stop":[127],"(TES),":[128],"extends":[129],"maximum":[133],"12":[136,145],"weeks":[137,146,166],"stops":[140],"after":[142,167,271],"two":[143],"injections,":[144],"apart,":[147],"if":[148,191],"\u201cdry":[150],"macula\u201d":[151],"maintained.":[153],"These":[154],"monitored":[158,181],"in":[159,238,245],"stepwise":[161],"fashion,":[162],"evaluating":[163],"them":[164],"four":[165],"stopped":[170],"increasingly":[173],"at":[174,216],"intervals":[176],"quarterly.":[182],"Re-initiation":[183],"TES":[186,236,273,278],"protocol":[187],"begun":[189],"immediately":[190],"recurrence":[193,233],"choroidal":[196],"neovascularization":[197],"(CNV)":[198],"occurs.":[199],"Using":[200],"this":[201],"method,":[202],"patients\u2019":[203],"vision":[204,260],"improved":[205],"from":[206],"20/70":[207],"20/50":[209,270],"(p<0.001),":[210],"approximately":[212],"7.5":[213],"ETDRS":[214],"letters":[215],"cessation,":[218],"with":[219,249],"an":[220,250],"average":[221,251],"22":[223],"over":[225],"years":[227],"active":[229],"treatment.":[230],"True":[231],"disease":[232,288],"using":[234],"eyes":[239],"that":[240],"ceased":[241],"therapy":[242,294],"observed":[244],"29.4%":[246],"eyes,":[248],"14":[253],"months":[254],"recurrence.":[258],"Average":[259],"initially":[261],"decreased":[262],"20/60":[264],"during":[265],"recurrence,":[266],"however":[267],"recovered":[268],"restarting":[272],"injection":[274],"protocol.":[275],"Thus,":[276],"strategy":[279],"may":[280],"provide":[281],"visual":[282],"improvement":[283],"stability,":[285],"remission":[289],"cessation":[291],"without":[295],"loss":[296],"vision.":[298]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2884954262","counts_by_year":[],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2018-08-03T00:00:00"}
